M Shrikhande
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: University of Bern (2000); St. John's University (2018–2020); Heidelberg University (2003); University of California San Diego Medical Center (2024)
Unknown Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
M Shrikhande's research primarily investigates the utilization and costs associated with treating patients who have Type-2 Diabetes and Cardiovascular Disease. This work specifically examines the use of Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists in patient care. Shrikhande has contributed to a publication in 2024 detailing these aspects.
With a career h-index of 2 and 180 total citations across 9 publications, Shrikhande has collaborated with researchers at the University of Arkansas for Medical Sciences, including Laura E. Gressler, Jacob T. Painter, and Christopher Johnson, with whom they share single publications.
Metrics
- h-index: 2
- Publications: 9
- Citations: 180
Selected Publications
-
EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists (2024)
Collaboration Network
Top Collaborators
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
Similar Researchers
Based on overlapping research topics